Title : Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.

Pub. Date : 2017 Mar

PMID : 28164434






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dual inhibition of Akt and c-Met by their respective inhibitors, MK2206 and capmatinib, additively or synergistically suppressed sorafenib-resistant HCC cells in vitro and sorafenib-resistant HCC xenografts in mice. Sorafenib met proto-oncogene Mus musculus
2 Dual inhibition of Akt and c-Met by their respective inhibitors, MK2206 and capmatinib, additively or synergistically suppressed sorafenib-resistant HCC cells in vitro and sorafenib-resistant HCC xenografts in mice. Sorafenib met proto-oncogene Mus musculus